Comparative bioavailability of two carbamazepine tablets.
The comparative bioavailability of two commercial carbamazepine tablets (Finlepsin and Tegretol) was investigated. In a single-dose study in eight healthy volunteers and in a multiple-dose study in five epileptic patients carbamazepine absorption from both drug products was shown to have the same extent and reliability. Despite a somewhat increased rate of absorption in Finlepsin, as regards the fit of the drug level in the therapeutic range under chronic treatment conditions, there was no difference between the two preparations. On the basis of these results we conclude that Finlepsin and Tegretol are bioequivalent drug products.